Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SI | P14410 | 1/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929216 | 0.85 | POLB (0.49) | POLBL3MBTL1LMNAKMT2AKDM4E | |
| SCHEMBL509740 | 0.84 | SIRT6 (0.46) | L3MBTL1KMT2AMGAMGAASI | |
| SCHEMBL1644521 | 0.79 | POLB (0.70) | POLBL3MBTL1LMNAKMT2AALDH1A1 | |
| SCHEMBL2218231 | 0.79 | L3MBTL1 (0.62) | POLBL3MBTL1LMNAKMT2AALDH1A1 | |
| SCHEMBL11720926 | 0.79 | GAA (0.44) | KMT2AMGAMGAASIMGAM2 | |
| SCHEMBL509677 | 0.79 | POLB (0.52) | POLBKMT2AKDM4EMAPTHPGD | |
| SCHEMBL10072456 | 0.78 | POLB (0.50) | POLBL3MBTL1LMNAKMT2AGAA | |
| SCHEMBL15176143 | 0.78 | KDM4E (0.44) | POLBKMT2AMGAMGAASI | |
| SCHEMBL5269058 | 0.77 | POLB (0.46) | POLBL3MBTL1LMNAKMT2AGAA | |
| SCHEMBL23013933 | 0.76 | CXCR1 (0.43) | POLBL3MBTL1LMNAKMT2AMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2008152418-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | WO | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-4144339-A | TREATMENT OF BILHARZIASIS | RHONE-POULENC INDUSTRIES (FR) | 1979-03-13 | — | — | US | disclosed |
| US-4138487-A | NEMATOCIDES | RHONE-POULENC INDUSTRIES (FR) | 1979-02-06 | — | — | US | disclosed |
| US-4110450-A | BILHARZIASIS | RHONE-POULENC INDUSTRIES (FR) | 1978-08-29 | — | — | US | disclosed |
| US-4058611-A | PYRAZINYL, BILHARZIASIS, AMOEBIASIS | RHONE-POULENC INDUSTRIES (FR) | 1977-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | POLB 1019/4885L3MBTL1 4676/4885LMNA 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.